Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion

Atrial Fibrillation Clinical Trial

— PRE-ELECTRIC  

Official title:

Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03346863
• Other study ID #: PRE-ELECTRIC 2017/1604
• Status: Recruiting
• Start date: November 1, 2017
• Est. completion date: December 2023

Study information

• Verified date: April 2021
• Source: Vestre Viken Hospital Trust
• Contact: Arnljot Tveit, MD, PhD
• Phone: 0047-97171773
• Email: arnljot.tveit[@]vestreviken.no
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In patients with persistent atrial fibrillation (AF), electrical cardioversion is very effective in restoring sinus rhythm if modern, biphasic cardioverters are used. However, approximately 50 per cent of the successfully cardioverted patients experience a recurrence of AF within a few weeks. Therefore, valid predictors for AF recurrence would be of great clinical relevance, to avoid unnecessary procedures.

In the PRE-ELECTRIC study, we will investigate the predictive value of potential new biomarkers with respect to AF recurrence within 30 days after electrical cardioversion. We will investigate serum and plasma biomarkers, electrocardiological markers and echocardiographic variables in this respect. The study will be undertaken as a prospective cohort study at Bærum Hospital, Vestre Viken Hospital Trust, with national and international collaborators.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 270
• Est. completion date: December 2023
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients > 18 years referred for electrical cardioversion for persistent atrial fibrillation

• Signed, informed consent

Exclusion Criteria:

• Patients < 18 years

• Patients with paroxysmal atrial fibrillation

• Patients unwilling to participate or without consent competence

Related Conditions & MeSH terms

• Atrial Fibrillation
• Recurrence

Locations

Country	Name	City	State
Norway	Bærum Hospital, Vestre Viken	Sandvika	Bærum

Sponsors (3)

Lead Sponsor	Collaborator
Vestre Viken Hospital Trust	Lund University, Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Atrial fibrillation recurrence	ECG-documented atrial fibrillation recurrence after successful cardioversion	30 days after electrical cardioversion